Camurus

Camurus company information, Employees & Contact Information

Explore related pages

Related company profiles:

Camurus is a Swedish science-led biopharmaceutical company committed to improving the lives of patients with severe and chronic diseases. We empower patients, support caregivers and create value for society by developing and giving access to innovative, long-acting medicines. To fulfill our commitment, we are determined to conduct our business in a sustainable manner. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® technology and extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of treatment of opioid dependence, cancer, and endocrine disorders, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX.

Company Details

Employees
262
Founded
-
Address
Ideon Science Park, Lund,skåne 223 70,sweden
Phone
46462865730
Email
in****@****rus.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Lund, Skåne
Looking for a particular Camurus employee's phone or email?

Camurus Questions

News

Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK - Yahoo Finance

Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK Yahoo Finance

Exercise in Camurus' employee stock options program 2022/2026 - TradingView

Exercise in Camurus' employee stock options program 2022/2026 TradingView

Eli Lilly Bets $870M on Camurus FluidCrystal Tech to Transform Diabetes and Obesity Treatment - Stock Titan

Eli Lilly Bets $870M on Camurus FluidCrystal Tech to Transform Diabetes and Obesity Treatment Stock Titan

Lilly partners with Camurus in search of a long-lasting obesity drug - BioPharma Dive

Lilly partners with Camurus in search of a long-lasting obesity drug BioPharma Dive

Sweden’s drugmaker Camurus eyes US expansion with potential Braeburn buyout - European Interest

Sweden’s drugmaker Camurus eyes US expansion with potential Braeburn buyout European Interest

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins - Yahoo Finance

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins Yahoo Finance

Eli Lilly enlists Camurus to help unlock long-acting obesity market in deal worth up to $870M - Fierce Biotech

Eli Lilly enlists Camurus to help unlock long-acting obesity market in deal worth up to $870M Fierce Biotech

Camurus CEO sells shares - TradingView

Camurus CEO sells shares TradingView

Swedish Biotech Camurus in Talks to Buy US-Based Braeburn in $1 Billion Opioid Market Bet - EU Reporter

Swedish Biotech Camurus in Talks to Buy US-Based Braeburn in $1 Billion Opioid Market Bet EU Reporter

Big Pharma Deal: Swedish Camurus to Acquire US Braeburn? - Modern Diplomacy

Big Pharma Deal: Swedish Camurus to Acquire US Braeburn? Modern Diplomacy

Eli Lilly and Camurus enter cardiometabolic health partnership worth up to $870m - PMLiVE

Eli Lilly and Camurus enter cardiometabolic health partnership worth up to $870m PMLiVE

Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU - Yahoo Finance

Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU Yahoo Finance

US FDA declines to approve Camurus' rare hormone disorder drug - Reuters

US FDA declines to approve Camurus' rare hormone disorder drug Reuters

Lilly targets long-acting obesity market in $870 million Camurus deal - The Pharma Letter

Lilly targets long-acting obesity market in $870 million Camurus deal The Pharma Letter

Camurus preps for Phase III after long-acting octreotide clears mid-stage study in liver disease - FirstWord Pharma

Camurus preps for Phase III after long-acting octreotide clears mid-stage study in liver disease FirstWord Pharma

Camurus Q1 2025 slides: record profitability despite market challenges - Investing.com

Camurus Q1 2025 slides: record profitability despite market challenges Investing.com

FDA stymies Camurus' hormonal disorder drug due to 3rd-party manufacturing issues - Fierce Pharma

FDA stymies Camurus' hormonal disorder drug due to 3rd-party manufacturing issues Fierce Pharma

FDA Action Alert: Amgen, Camurus, Iterum and Lexicon - BioSpace

FDA Action Alert: Amgen, Camurus, Iterum and Lexicon BioSpace

Octreotide CAM2029 Returns Positive Results for the Treatment of Acromegaly in ACROINNOVA 2 Phase III Study - Applied Clinical Trials

Octreotide CAM2029 Returns Positive Results for the Treatment of Acromegaly in ACROINNOVA 2 Phase III Study Applied Clinical Trials

Eli Lilly, Camurus in major deal to develop obesity, diabetes drugs (LLY:NYSE) - Seeking Alpha

Eli Lilly, Camurus in major deal to develop obesity, diabetes drugs (LLY:NYSE) Seeking Alpha

Argenx’s Vyvgart, Camurus’ Oczyesa among 16 recommended by CHMP - BioWorld MedTech

Argenx’s Vyvgart, Camurus’ Oczyesa among 16 recommended by CHMP BioWorld MedTech

Congratulations to MVA member Camurus’ CEO Fredrik Tiberg with the The Arthur D. Little Nordic Life Science Award - mva.org

Congratulations to MVA member Camurus’ CEO Fredrik Tiberg with the The Arthur D. Little Nordic Life Science Award mva.org

After a year of 4.6% returns, Camurus AB (publ)'s (STO:CAMX) share price drop last week may have less of an impact on institutional investors - simplywall.st

After a year of 4.6% returns, Camurus AB (publ)'s (STO:CAMX) share price drop last week may have less of an impact on institutional investors simplywall.st

Camurus and Eli Lilly collaborate on long-acting incretin products - Pharmaceutical Business review -

Camurus and Eli Lilly collaborate on long-acting incretin products Pharmaceutical Business review -

Camurus wins EU approval for acromegaly treatment Oczyesa - The Pharma Letter

Camurus wins EU approval for acromegaly treatment Oczyesa The Pharma Letter

Eli Lilly signs near billion-dollar deal with Swedish biotech Camurus - medwatch.com

Eli Lilly signs near billion-dollar deal with Swedish biotech Camurus medwatch.com

A GATEWAY WITHIN ALL WOMEN'S REACH - Dianova International

A GATEWAY WITHIN ALL WOMEN'S REACH Dianova International

FDA Rejects Camurus’ Rare Hormonal Disorder Treatment Due to Manufacturing Problems - BioSpace

FDA Rejects Camurus’ Rare Hormonal Disorder Treatment Due to Manufacturing Problems BioSpace

Lilly Inks Deal Worth up to $870M To Develop Long-Acting GLP-1 Obesity Drugs - BioSpace

Lilly Inks Deal Worth up to $870M To Develop Long-Acting GLP-1 Obesity Drugs BioSpace

Redeye: Camurus Q2 2025 - Deal with Eli Lilly - TradingView

Redeye: Camurus Q2 2025 - Deal with Eli Lilly TradingView

Long-Acting Octreotide Therapy Gets Orphan Drug Status for Polycystic Liver Disease - Medical Professionals Reference

Long-Acting Octreotide Therapy Gets Orphan Drug Status for Polycystic Liver Disease Medical Professionals Reference

Eli Lilly (LLY) Expands With Camurus Partnership for Metabolic T - GuruFocus

Eli Lilly (LLY) Expands With Camurus Partnership for Metabolic T GuruFocus

There's No Escaping Camurus AB (publ)'s (STO:CAMX) Muted Revenues Despite A 27% Share Price Rise - simplywall.st

There's No Escaping Camurus AB (publ)'s (STO:CAMX) Muted Revenues Despite A 27% Share Price Rise simplywall.st

Camurus and Braeburn Pharmaceuticals sign exclusive license for long-acting buprenorphine injectables for the treatment of opioid dependence and pain - PR Newswire

Camurus and Braeburn Pharmaceuticals sign exclusive license for long-acting buprenorphine injectables for the treatment of opioid dependence and pain PR Newswire

Camurus, Eli Lilly Collaborate for Long-Acting Incretin Products Using FluidCrystal Technology - Insider Monkey

Camurus, Eli Lilly Collaborate for Long-Acting Incretin Products Using FluidCrystal Technology Insider Monkey

Peptron rebounds after Lilly-backed obesity deal seen unaffected by Camurus pact - koreabiomed.com

Peptron rebounds after Lilly-backed obesity deal seen unaffected by Camurus pact koreabiomed.com

Camurus signs billion-dollar deal with Eli Lilly - Biostock

Camurus signs billion-dollar deal with Eli Lilly Biostock

Sweden: Camurus carries out directed share issue to raise SEK1.09bn - Investors in Healthcare

Sweden: Camurus carries out directed share issue to raise SEK1.09bn Investors in Healthcare

Braeburn, Camurus seek FDA nod for buprenorphine depot - Drug Delivery Business

Braeburn, Camurus seek FDA nod for buprenorphine depot Drug Delivery Business

Eli Lilly, a global pharmaceutical company, has joined hands with Sweden's Camurus to target the lon.. - 매일경제

Eli Lilly, a global pharmaceutical company, has joined hands with Sweden's Camurus to target the lon.. 매일경제

Rhythm, Camurus tout early data on setmelanotide in rare genetic obesity - Drug Delivery Business

Rhythm, Camurus tout early data on setmelanotide in rare genetic obesity Drug Delivery Business

Buprenorphine Conversions - MedCentral

Buprenorphine Conversions MedCentral

Camurus Receives Option-exercise Milestone for Octreotide FluidCrystal® Product CAM2029 - PR Newswire

Camurus Receives Option-exercise Milestone for Octreotide FluidCrystal® Product CAM2029 PR Newswire

Braeburn Licenses Camurus’ CAM2038 for Up-to-$151M - Genetic Engineering and Biotechnology News

Braeburn Licenses Camurus’ CAM2038 for Up-to-$151M Genetic Engineering and Biotechnology News

BPS Publications - British Pharmacological Society | Journals

BPS Publications British Pharmacological Society | Journals

Camurus - carnegie.se

Camurus carnegie.se

Top Camurus Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant